- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Alto Neuroscience Reports Positive Phase 2 Data for ALTO-101
Biotech firm highlights progress on mental health drug pipeline
Apr. 1, 2026 at 10:28pm
Got story updates? Submit your updates here. ›
Alto Neuroscience, a clinical-stage biopharmaceutical company, has announced positive topline data from a Phase 2 proof-of-concept study of its investigational drug ALTO-101 for the treatment of depression and anxiety. The company also provided updates on the advancement of its broader pipeline of central nervous system (CNS) drug candidates.
Why it matters
The positive results for ALTO-101 represent an important milestone for Alto Neuroscience as it works to develop new treatment options for mental health conditions. If approved, ALTO-101 could provide an alternative therapy for patients who do not respond well to existing antidepressant and anti-anxiety medications.
The details
The Phase 2 study evaluated the safety, tolerability, and preliminary efficacy of ALTO-101 in adults with moderate-to-severe depression and/or anxiety. The company reported that ALTO-101 met the primary and key secondary endpoints, demonstrating statistically significant improvements in depression and anxiety symptoms compared to placebo. Alto Neuroscience also highlighted advancements in its pipeline, including the initiation of a Phase 2 study for its lead program ALTO-201 in major depressive disorder.
- The Phase 2 proof-of-concept study of ALTO-101 was conducted in 2025.
- Alto Neuroscience announced the topline data results on April 1, 2026.
The players
Alto Neuroscience
A clinical-stage biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders.
ALTO-101
Alto Neuroscience's investigational drug candidate for the treatment of depression and anxiety.
ALTO-201
Alto Neuroscience's lead program, a drug candidate for the treatment of major depressive disorder.
What they’re saying
“We are very encouraged by the positive results from the Phase 2 proof-of-concept study of ALTO-101, which represent an important milestone in our efforts to develop new treatment options for patients suffering from depression and anxiety.”
— Amit Etkin, Founder and CEO of Alto Neuroscience
What’s next
Alto Neuroscience plans to initiate a Phase 3 clinical trial for ALTO-101 later this year to further evaluate the drug's efficacy and safety.
The takeaway
The positive data for ALTO-101 highlights Alto Neuroscience's progress in advancing its pipeline of novel CNS drug candidates, which could provide new treatment options for patients with mental health conditions that are not adequately addressed by existing therapies.
